RPRX Share Price Performance
US$38.67
12.66 (48.67%)
20.1% overvalued intrinsic discount
US$32.19
Fair Value
Price US$38.67
AnalystLowTarget US$32.19
AnalystConsensusTarget US$45.98
AnalystHighTarget US$54.36
Fair ValueUS$37.00
Share Pricen/a
Royalty Pharma plc Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 46 Fair Values set on narratives written by author
RPRX Community Narratives
AN
Fair Value US$37 4.5% overvalued intrinsic discount
Royalty Revenue Will Contract Amid Strict Pricing And Debt Pressures
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$45.98 15.9% undervalued intrinsic discount
RPRX: Upcoming Licensing Deals And Share Buybacks Will Drive Long-Term Upside
0users have liked this narrative
0users have commented on this narrative
24users have followed this narrative
AN
Fair Value US$55 29.7% undervalued intrinsic discount
Expanding Global Pharmaceutical R&D Will Unlock Blockbuster Royalty Deals
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
RPRX: Upcoming Licensing Deals And Share Buybacks Will Drive Long-Term Upside
Key Takeaways Sustained demand for innovative therapies and strategic global investments are driving long-term portfolio growth and geographic diversification. Efficient cash reinvestment, operational streamlining, and early participation in high-value assets are boosting margins and shareholder returns.Read more
0users have liked this narrative
0users have commented on this narrative
24users have followed this narrative
AN
US$45.98
15.9% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
18.52% p.a.
Profit Margin
31.35%
Future PE
18.76x
Price in 2028
US$56.19
Royalty Revenue Will Contract Amid Strict Pricing And Debt Pressures
Key Takeaways Political and regulatory pressures on drug pricing, along with weaker intellectual property protections, threaten future royalty streams and earnings stability. Rising interest rates and intensified competition for assets risk shrinking margins, slowing acquisitions, and eroding the company's historical returns.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$37
4.5% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue
15.45% p.a.
Profit Margin
25.2%
Future PE
27.06x
Price in 2028
US$60.75
Expanding Global Pharmaceutical R&D Will Unlock Blockbuster Royalty Deals
Key Takeaways Structural cost improvements and proactive deal-making are driving margin expansion and positioning the company for sustained earnings growth above consensus. Agile business model and strong industry relationships enable access to untapped royalty opportunities, accelerating portfolio diversification and high-return transactions.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$55
29.7% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue
23.17% p.a.
Profit Margin
20.75%
Future PE
40.22x
Price in 2028
US$90.3
Trending Discussion
Recently Updated Narratives
AN
RPRX: Share Buybacks Will Drive Value Upon Acquisition Completion
Fair Value: US$45.98 15.9% undervalued intrinsic discount
24 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Expanding Global Pharmaceutical R&D Will Unlock Blockbuster Royalty Deals
Fair Value: US$55 29.7% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Royalty Revenue Will Contract Amid Strict Pricing And Debt Pressures
Fair Value: US$37 4.5% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Royalty Pharma plc Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- 1.79
- 106.59%
- 32.55%
- 93.0%
About RPRX
- Founded
- 1996
- Employees
- n/a
- CEO
- WebsiteView website
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
